David Brannon Johnston

David Brannon Johnston is a declared insider at 2 companies; the most frequent names are Aveo Pharmaceuticals, Inc. and ImmunoGen, Inc. Over a trading history stretching from 15 February 2011 to 6 June 2018, the count stands at 33 filings.

In open-market terms, that means 1 purchase worth €15k on one side and 16 sales worth €841k on the other. Taken together, the sales exceed the purchases by €825k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 5 share grants and 10 option exercises. So far in 2018, the count stands at no purchases and 3 sales.

Most recently, on 8 June 2018, the filings show an option exercise worth €26k in ImmunoGen, Inc. The most recent open-market purchase was published on 3 November 2016, 3,658 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.